Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan - Takeaways - MDSpire

Addressing MASLD/MASH: Obstacles, Innovations, and the Future of Patient-Centric Approaches in Japan

By
Yuya Seko
Kanji Yamaguchi
April 15, 2026

Journal Of Gastroenterology

Share

1

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in Japan increased from 21.8% to 30.3% between 2018 and 2019.
2

Lean MASLD accounts for 20.7% of the MASLD population in Japan, highlighting its occurrence in individuals with a BMI under 23 kg/m2.
3

Non-invasive liver disease assessment methods are advancing, enabling earlier diagnosis and management of MASLD/MASH in Japan.
4

Emerging therapies for MASH, including lifestyle changes and medications like resmetirom and semaglutide, are transforming treatment strategies.
5

Challenges in managing MASLD/MASH include a lack of standardized guidelines and the need for personalized treatment approaches.

Original Source(s)

Journal Of Gastroenterology

Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan

by Yuya Seko, Kanji Yamaguchi
April 15, 2026

Related Content

Barnes-Jewish

Expanding Access to Liver Transplant: Why Barnes-Jewish Hospital and WashU Medicine Launched an Adult Living Donor Program

For hepatologists and other physicians who treat patients with advanced liver disease, the gap between the number of patients who need transplant and the number of available organs is a familiar challenge.

by
June 17, 2026
5 min

Jama Network Open

Sex Differences in Long-Term Overall and Cause-Specific Mortality in Patients With Cirrhosis

Updates In Surgery

Risk factors for inferior right hepatic vein occlusion following right lobe living donor liver transplantation: a single-center experience with 240 cases